Novartis COPD Drug Wil Test The LABA Safety Waters During Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Given the known risks of long-acting beta-2 agonists, a safety discussion seems likely when the Pulmonary-Allergy Drugs Advisory Committee meets to review Novartis' Arcapta Neohaler (indacaterol maleate).